Rathmell: We must support our junior colleagues

“Empathy and listening is a key place to start”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Dear Colleagues,

Are you feeling the sting of budget cuts, stalled review panels, and widespread uncertainty in the direction of medicine and biomedical research? 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Top row (left to right): Dirk Görlich, Steven L. McKnight, Michael J. Welsh.Bottom row (left to right): Jesús (Tito) González, Paul A. Negulescu, Lucy ShapiroThe 2025 Albert Lasker Basic Medical Research Award honors went to two scientists for discoveries that exposed the structures and functions of low-complexity domains  within protein sequences. 
Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.
Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. 
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login